What guidance can you give when the F1M CGP profile reveals multiple relevant, actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist?

What guidance can you give when the F1M CGP profile reveals multiple relevant, actionable mutations? Why select targeted therapies when multiple genomic alterations or rearrangements co-exist?

What guidance can you give in those cases in which the F1M CGP profile reveals multiple relevant, actionable mutations? On what basis would you select targeted therapies when multiple significant genomic alterations or rearrangements co-exist?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Samuel Klempner, MD

Samuel Klempner, MD

Director of Precision Medicine
The Angeles Clinic and Research Institute
Cedars-Sinai Medical Center
Los Angeles, CA